Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

Upcoming Events

Calendar Review
JCCC and UCLA IIIT Seminar Featuring Dr. James Kochenderfer
Treatment of Hematologic Malignancies with Chimeric Antigen Receptor T Cells
Date: 10/21/2014
Time: 12:00 PM - 1:00 PM
Cost: Free
Location: NRB Auditorium
Los Angeles, California 90095

JCCC SeminarDr. James Kochenderfer

Presented by:
James Kochenderfer, M.D.
Investigator, Experimental Transplantation and Immunology Branch
Center for Cancer Research
National Cancer Institute

Dr. Kochenderfer's research is aimed at developing T-cell therapies for hematogic malignancies and genetic engineering of T cells with genes encoding chimeric antigen receptors that target malignancy-associated antigens. This work has led to two clinical trials in which patients receive infusions of T cells that are genetically engineered to specifically recognize and eliminate cells expressing the CD19 antigen, which is expressed by most B-cell lymphomas and B-cell leukemias. These clinical trials have produced the first evidence that genetically-engineered T cells can eliminate CD19-expressing cells in humans.

Light lunch served

Co-sponsored by the David Geffen School of Medicine Initiative in Immunity, Inflammation, Infection, and Transplantation (I3T), the Jonsson Comprehensive Cancer Center, and the Center for AIDS Research